Minimal residual disease (MRD) detection acts a critical role in the management of lymphoma. Traditionally, MRD assessment depends on invasive bone marrow biopsies, which can be carry risks and discomfort for patients. Liquid biopsy, a minimally invasive approach, has emerged as a promising alternative for MRD detection in lymphoma. This approach i